Abstract: A prepreg containing at least the following components [A] to [D], wherein the prepreg includes: a first layer in which the component [A] is impregnated with a first resin composition containing the components [B] and [C]; and a second layer that contains a second resin composition containing the components [B] to [D] and is formed on both surfaces of the first layer, and the first layer and the second layer are adjacent to each other, an average fiber diameter of a carbon fiber as the component [A] is 6 ?m or more and 9 ?m or less, and a content of a bifunctional amine type epoxy resin [B1] is 15 parts by mass or more and less than 40 parts by mass based on 100 parts by mass of a total amount of epoxy resin of the component [B]: [A] a carbon fiber; [B] an epoxy resin; [C] a curing agent; and [D] thermoplastic resin particles.

Abstract: A breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative or a salt thereof.

Abstract: The novel means by which an efficiency of ovum collection can be easily determined in bovine at gene level is disclosed. The present inventors performed the genomic linkage analysis using bovine populations with high and low efficiency of ovum collection and to identify GRIA1 gene, which encodes an ion channel protein, as a factor deeply related to an efficiency of ovum collection. Bovines having a mutation (e.g. the amino acid substitution of aa306) in GRIA1 produce significantly fewer ova on superovulatory treatment than those not having the mutation. Therefore, the efficiency of ovum collection can be determined based on the existence of a mutation in GRIA1 gene.

Abstract: Provided is a novel drug which exhibits excellent effect of inhibiting expression of an ABC transporter protein, as well as improved safety. An ABC transporter protein expression inhibitor containing, as an active ingredient, a substance which inhibits expression of one or more genes selected from the group consisting of ARHGAP17, CTDSP2, DUSP1, IMPA2, RHOBTB3, SGK, UBE2H, INPP5F, MAP2K6, PPM1E, PRKAG2, PRKCD, PTPN21, UBE2B, UBTF, and ZNF259.

Abstract: In an optical pickup, a photo receiving portion for receiving returned light reflected by an optical disc is adhered and fixed to an optical base. The photo receiving portion has a photodetector and a plate on which the photodetector is loaded. The plate is fixed onto the optical base by adhesive such that the photo receiving portion is adhered and fixed to the optical base. The plate is in a substantially circular shape in plan view.

Abstract: An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an anticancer drug; and cells useful in the development of an anticancer drug. The present invention provides a drug which inhibits the expression of an ABC transporter to thereby overcome resistance to anticancer drugs; cancer cells useful in screening such drugs; and an anticancer drug efficacious even against such a cancer as having acquired resistance to anticancer drugs.

Abstract: The present invention relates to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The invention provides an acrylonitrile derivative represented by formula (1): (wherein A represents an optionally substituted 3- to 8-membered heterocyclic ring) or a salt thereof.

Abstract: To provide an excellent agent for prevention or treatment of an inflammatory disease. The agent for prevention or treatment of an inflammatory disease contains a thymidine phosphorylase inhibitor as an active ingredient, wherein when the thymidine phosphorylase inhibitor is 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or a salt thereof, the inflammatory disease is an inflammatory disease other than inflammatory bowel disease.

Abstract: The novel means by which an efficiency of ovum collection can be easily determined in bovine at gene level is disclosed. The present inventors performed the genomic linkage analysis using bovine populations with high and low efficiency of ovum collection and to identify GRIA1 gene, which encodes an ion channel protein, as a factor deeply related to an efficiency of ovum collection. Bovines having a mutation (e.g. the amino acid substitution of aa306) in GRIA1 produce significantly fewer ova on superovulatory treatment than those not having the mutation. Therefore, the efficiency of ovum collection can be determined based on the existence of a mutation in GRIA1 gene.

Abstract: The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R1 and R2 represents a cyano group and the other represents a hydrogen atom; Ar1 represents a group selected from among the groups represented by formulas (2) to (4): and Ar2 represents an aromatic hydrocarbon group having a condensed ring which may be substituted by a halogen atom, or a group selected from among the groups represented by the following formulas (5) to (15): or a salt thereof.

Abstract: A Ras, Raf, MEK, ERK or RSK inhibitor, namely a P-glycoprotein expression inhibitor or a BCRP expression inhibitor, can be screened by utilizing the MAPK signaling activity as an indicator. It becomes possible to provide an anticancer agent which is reduced in resistance acquisition, and also provide an agent for preventing the resistance against an anticancer agent, which can enhance the therapeutic effect of the anticancer agent against cancer.

Abstract: To establish an immunoassay method for human OPRT. The method for assaying human orotate phosphoribosyltransferase protein includes employing, in combination, an anti-human orotate phosphoribosyltransferase antibody which recognizes an epitope present in a region of 86th to 108th amino acid residues from the N-terminus of human orotate phosphoribosyltransferase, and an anti-human orotate phosphoribosyltransferase antibody which recognizes an epitope present in a region of 454th to 474th amino acid residues from the N-terminus of human orotate phosphoribosyltransferase.

Abstract: The invention provides a cancer cell useful in screening BCRP-inhibitors, and a BCRP-inhibitor. The BCRP-inhibitor contains, as the active ingredient, a flavonoid represented by any of the following formulae (1), (2), (3), (4), and (5): and glycosides, esters, or salts thereof; and an anticancer agent containing the BCRP-inhibitor together with an anticancer agent available as the substrate of BCRP.

Abstract: An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an anticancer drug; and cells useful in the development of an anticancer drug. The present invention provides a drug which inhibits the expression of an ABC transporter to thereby overcome resistance to anticancer drugs; cancer cells useful in screening such drugs; and an anticancer drug efficacious even against such a cancer as having acquired resistance to anticancer drugs.

Abstract: The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1?7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e.

Abstract: An optical pickup that improves recording and reproducing performances on a disc without increasing the cost includes first and second magnets. The first magnet is placed on protrusions provided to a first wall portion of a base of an actuator portion. Both end portions of the bottom surface of the first magnet, the first wall portion on a surface facing a second wall portion, and a pedestal are adhered together by using an UV adhesive. Similarly, a second magnet is placed on protrusions provided to the second wall portion of the base. Both end portions of the bottom surface of the second magnet, the second wall portion on a surface facing the first wall portion, and a pedestal are adhered together by using an UV adhesive.

Abstract: The invention provides a cancer cell useful in screening BCRP-inhibitors, and a BCRP-inhibitor. The BCRP-inhibitor contains, as the active ingredient, a flavonoid represented by any of the following formulae (1), (2), (3), (4), and (5): and glycosides, esters, or salts thereof; and an anticancer agent containing the BCRP-inhibitor together with an anticancer agent available as the substrate of BCRP.

Abstract: The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1 (R1 is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2 (n=1?7: R2 is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e.

Abstract: A method for gene diagnosis of bovine Hsp70 deficiency, which comprises (a) a step of obtaining a bovine nucleic acid sample, (b) a step of subjecting the nucleic acid sample obtained in step (a) to a gene amplification reaction to obtain a nucleic acid fragment in which a region including a mutation site likely to be present in bovine Hsp70 gene is amplified, and (c) a step of examining the presence of mutation on the nucleic acid fragment in step (b), the region including the mutation site being a region including 1997-11030 position of a base sequence shown in SEQ ID No. 1 of SEQUENCE LISTING in a base sequence of bovine Hsp70 gene. According to the invention, bovine Hsp70 deficiency and its carrier can be detected and diagnosed by a genetic engineering method easily and quickly, and a kit used for this purpose is provided.

Abstract: This invention provides a double-stranded oligonucleotide or a derivative thereof which comprises 15 to 40 base pairs, wherein at least one side of the strands contains at least one nucleotide sequence represented by 5'-TTTSSCGS-3' (S is G or C). Also, since the compound of the present invention can inhibit expression of growth-related genes which are regulated by E2F, through its function to undergo sequence-specific competitive inhibition of the binding of E2F protein to the transcription region at a low concentration, a pharmaceutical composition containing the inventive compound as its active ingredient is useful as a drug having low side effects for use in the prevention and treatment of cancers.